Clavoclav 625 Tablets contain a powerful combination of Amoxycillin and Potassium Clavulanate, designed to treat a wide range of bacterial infections caused by beta-lactamase–producing organisms. Amoxycillin works by inhibiting bacterial cell wall synthesis, while Clavulanate potassium enhances its effectiveness by preventing bacterial resistance.

This combination is commonly prescribed for respiratory tract infections, urinary tract infections, skin and soft tissue infections, dental infections, and ENT infections. Clavoclav 625 is well-tolerated and widely trusted by healthcare professionals for its proven efficacy and reliability.

Manufactured under strict quality control standards, Clavoclav 625 ensures consistent therapeutic performance and patient safety when used as directed by a qualified medical practitioner.